| Literature DB >> 25249356 |
Ulrika Windahl, Bodil Ström Holst, Ann Nyman, Ulrika Grönlund, Björn Bengtsson.
Abstract
BACKGROUND: Bacterial urinary tract infection (UTI) is a common reason for antimicrobial therapy in dogs. A reported increase in multi-drug resistance in canine bacterial pathogens, including resistance to extended-spectrum cephalosporins (ESC) is of concern as antimicrobial resistance complicates therapy in dogs. In addition, it is a possible public health concern. The objectives of this study were to investigate the relative prevalence of pathogens in urine samples from dogs with urinary tract infection sampled at referral hospitals, clinics and mixed veterinary practices and to investigate if this was influenced by sample material or by contamination of the culture. The second objective was to assess the susceptibility patterns to clinically relevant antimicrobials and to investigate if this was influenced by whether the samples originated from smaller clinics or from referral hospitals and to perform active screening for the presence of Enterobacteriaceae resistant to ESC.Entities:
Mesh:
Year: 2014 PMID: 25249356 PMCID: PMC4180317 DOI: 10.1186/s12917-014-0217-4
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Findings of uropathogens in submitted urinary samples presented by submission category, sample material and growth
|
|
|
| |||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
| |
|
| 45 (284) | 25 (154) | 30 (185) | 68 (423) | 32 (200) | 60 (375) | 40 (248) |
|
| 52 (25) | 33 (16) | 13 (7) | 83 (40) | 17 (8) | 58 (28) | 42 (20) |
|
| 43 (160) | 29 (107) | 28 (104) | 26 (95) | 74 (276) | 0 | 0 |
The relative prevalence (%) is presented with the number of samples shown inside brackets.
Relative prevalence of uropathogens in non-repeated urinary samples from individual dogs
|
|
|
|
|
|
|
|
|
|
| |||||||
| Pure growth, (n = 174) | 72 (131) | 57 (16) | 77 (10) | 78 (7) | 57 (4) | 71 (5) | 33 (1) |
| Contaminated growth, (n = 74) | 28 (50) | 43 (12) | 23 (3) | 22 (2) | 43 (3) | 29 (2) | 67 (2) |
|
| |||||||
| Pure growth, (n = 22) | 74 (17) | 50 (2) | 25 (1) | 50 (2) | - | 0 (0) | - |
| Contaminated growth, (n = 14) | 26 (6) | 50 (2) | 75 (3) | 50 (2) | - | 100 (1) | - |
|
|
|
|
|
|
|
|
|
|
| |||||||
| Pure growth, (n = 53) | 68 (42) | 67 (6) | 33 (3) | 0 (0) | 0 (0) | 100 (2) | 0 (0) |
| Contaminated growth, (n = 34) | 32 (20) | 33 (3) | 67 (6) | 100 (2) | 100 (1) | 0 (0) | 100 (2) |
|
| |||||||
| Pure growth, (n = 34) | 52 (25) | 67 (2) | 75 (6) | 0 (0) | - | 33 (1) | - |
| Contaminated growth, (n = 33) | 48 (23) | 33 (1) | 25 (2) | 100 (5) | - | 67 (2) | - |
|
|
|
|
|
|
|
|
|
|
| |||||||
| Pure growth, (n = 45) | 52 (29) | 50 (6) | 67 (6) | 25 (1) | 100 (2) | 33 (1) | 0 (0) |
| Contaminated growth, (n = 43) | 48 (27) | 50 (6) | 33 (3) | 75 (3) | 0 (0) | 67 (2) | 100 (2) |
|
| |||||||
| Pure growth, (n = 47) | 51 (30) | 50 (2) | 50 (6) | 36 (4) | - | 43 (3) | 50 (2) |
| Contaminated growth, (n = 50) | 49 (29) | 50 (2) | 50 (6) | 64 (7) | - | 57 (4) | 50 (2) |
|
| 68 (429) | 10 (60) | 9 (55) | 5 (35) | 2 (10) | 4 (23) | 2 (11) |
The relative prevalence (%) is presented by the three submission categories; small animal referral hospitals, small animal clinics and mixed veterinary practices are labelled A, B and C, respectively, as well as by submitted sample material and by pure- or contaminated growth. The number of samples is shown inside brackets.
Antimicrobial susceptibility (%) of , spp. and in non-repeated samples
|
|
|
|
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
| Ampicillin | ≤ 8 | 87.9 | 91.2 | 85.5 | 84.3 | 0.0 | 0.0 | 0.0 | 0.0 | 90.9 | 88.2 | 94.1 | 90.5 |
| Amoxicillin/Clavulanic acid | ≤ 8 | 87.2 | 89.7 | 85.5 | 84.3 | 72.7 | 66.7 | 100 | 66.7 | 94.5 | 100 | 94.1 | 90.5 |
| Cefotaxime | ≤ 1 | 99.8 | 99.5 | 100 | 100 | 100 | 100 | 100 | 100 | 98.2 | 100 | 94.1 | 100 |
| Gentamicin | ≤ 2 | 94.9 | 95.1 | 93.6 | 95.7 | 90.9 | 100 | 100 | 83.3 | 83.6 | 82.4 | 82.4 | 85.7 |
| Enrofloxacin | ≤ 0.5 | 97.9 | 98.5 | 95.5 | 99.1 | 90.9 | 100 | 100 | 83.3 | 96.4 | 100 | 88.2 | 100 |
| Tetracycline | ≤ 4 | 92.1 | 95.1 | 90.0 | 88.7 | 100 | 100 | 100 | 100 | 5.5 | 5.9 | 5.9 | 4.8 |
| Trimethoprim/Sulphametoxazole | ≤ 2/38 | 92.3 | 96.6 | 89.1 | 87.8 | 90.9 | 100 | 100 | 83.3 | 89.1 | 88.2 | 88.2 | 90.5 |
| Nitrofurantoin | ≤ 32 | 98.4 | 99.5 | 98.2 | 96.5 | 27.3 | 33.3 | 50.0 | 16.7 | 9.1 | 5.9 | 11.8 | 9.5 |
Breakpoints for susceptibility (BP S) (mg/L) are indicated. The number of samples is shown inside brackets. The three submission categories; small animal referral hospitals, small animal clinics and mixed veterinary practices are labelled A, B and C, respectively.
Resistance phenotypes of the 17 multidrugresistant isolates
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| 3 |
|
|
|
|
| |
| 1 |
|
|
|
| ||
| 1 |
|
|
|
| ||
| 11 |
|
|
| |||
| 1 |
|
|
|
The letter “R” in bold indicates resistance.
Antimicrobial susceptibility (%) of , , beta haemolytic streptococci and enterococci in non-repeated samples
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||
|
|
|
|
|
|
|
|
| |
| Penicillin | β-lacta | 10.0 | β-lact | 30.0 | ≤ 0.12 | 100 | ≤ 8 | NR |
| Ampicillin | β-lact | 10.0 | β-lact | 30.0 | ≤ 0.25 | NR | ≤ 8 | 87.0 |
| Amoxicillin/Clavulanic acid | ≤ 8 | 96.7 | ≤ 8 | 100 | ≤ 8 | 100 | ≤ 8 | 82.6 |
| Cephalothin | ≤ 2 | 98.3 | ≤ 2 | 100 | ≤ 2 | 100 | ≤ 2 | 13.0 |
| Oxacillin | ≤ 0.25 | NRb | ≤ 2 | 100 | - | - | - | - |
| Gentamicin | ≤ 2 | 98.3 | ≤ 2 | 100 | ≤ 2 | 0.0 | ≤ 2 | 30.4 |
| Erythromycin | ≤ 0.5 | 86.7 | ≤ 0.5 | 100 | ≤ 0.25 | NR | ≤ 0.5 | 34.8 |
| Enrofloxacin | ≤ 0.5 | 98.3 | ≤ 0.5 | 100 | ≤ 0.5 | 15.2 | ≤ 0.5 | 47.8 |
| Tetracycline | ≤ 4 | 66.7 | ≤ 4 | 90.0 | ≤ 2 | 63.6 | ≤ 4 | 65.2 |
| Trimethoprim/Sulphametoxazole | ≤ 2/38 | 95.0 | ≤ 2/38 | 100 | ≤ 2/38 | 100 | ≤ 2/38 | 87.0 |
| Nitrofurantoin | ≤ 32 | 100 | ≤ 32 | 100 | ≤ 32 | 100 | ≤ 32 | 82.6 |
Breakpoints for susceptibility (BP S) (mg/L) are indicated. The number of samples is shown inside brackets. Results from the susceptibility testing of one beta-haemolytic streptococcus isolate were lost and are not presented.
aβ-lact = beta-lactamase production.
bNR = not relevant since the BP is outside of the range of concentrations tested.
Resistance phenotypes of the six multidrugresistant isolates
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 2 |
| S |
| S |
| S | |
| 1 |
| S | S | S |
|
| |
| 1 |
| S |
| S |
| S | |
| 1 |
| S |
| S |
|
| |
| 1a |
|
|
|
|
| S |
|
The letter “R” in bold indicates resistance.
a mecA carrier.